1. Scrip
  2. >>Archive

Once Sluggish Sleep Apnea Gets Active

 
• By Mary Stuart

The past year was a busy one in the sleep apnea sector of the respiratory market. All three major segments of the sleep apnea market--sleep testing equipment, continuous positive airway pressure (CPAP) devices, and therapeutic implants--were represented by the year's deals, which include four acquisitions and two venture financings, and we're not even counting the $4.9 billion acquisition of Respironics by Philips, which was announced at the tail end of 2007.

The past year was a busy one in the sleep apnea sector of the respiratory market. All three major segments of the sleep apnea market--sleep testing equipment, continuous positive airway pressure (CPAP) devices, and therapeutic implants--were represented by the year’s deals, which include four acquisitions and two venture financings, and we’re not even counting the $4.9 billion acquisition of Philips Respironics by Royal Philips Electronics NV, which was announced at the tail end of 2007. [See Deal]

Obstructive sleep apnea (OSA) is increasingly identified as a disorder that should absolutely be treated in its moderate to severe...

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.